WORLDTECH NEWS Global technology intelligence.Contact
AI SINGLE SOURCE

New OpenAI benchmark tests how well models reason through complex drug discovery tasks

Detailed image of microchip components viewed through a microscope lens.
Illustrative photo.Photo by Tima Miroshnichenko on PexelsOpenAI logo shown for identification only; no affiliation with or endorsement of WORLDTECH is implied.

What happened

Advanced computing models can reconstruct complex molecular structures with high accuracy, but predicting how potential drug compounds behave remains a challenge, according to a new medicinal chemistry benchmark introduced by OpenAI. At the xhigh reasoning setting, GPT-6 (large language model by OpenAI) Astra earned 95.4 percent of the available credit for reconstructing molecular structures. OpenAI is an artificial intelligence company based in San Francisco.

However, the model earned only about half the available credit for selecting compounds and predicting their numerical properties. Called MedChemBench, the evaluation tests whether models can connect molecular structures with experimental evidence to explain research findings, compare compounds, and predict their properties.

The benchmark draws on 117 published papers and patents and contains 761 distinct molecular structures across 99 problems. The findings highlight a gap between identifying chemical structures correctly and understanding how changes to those structures influence a potential drug’s behavior.

Sources & evidence